Vectura Group PLC  

(Public, LON:VEC)   Watch this stock  
Find more results for VEC
-1.00 (-0.65%)
Jan 27 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 151.75 - 158.50
52 week 113.25 - 171.50
Open 156.00
Vol / Avg. 862,318.00/298,874.00
Mkt cap 613.70M*
P/E     -
Div/yield     -
EPS -0.02*
Shares 402.48M
Beta     -
Inst. own     -
Jan 15, 2015
Vectura Group PLC at JPMorgan Healthcare Conference (Q&A Session)
Jan 15, 2015
Vectura Group PLC at JPMorgan Healthcare Conference
Dec 3, 2014
Vectura Group PLC at Berenberg European Conference
Nov 20, 2014
Vectura Group PLC at Jefferies Global Healthcare Conference - London
Nov 18, 2014
Half Year 2014 Vectura Group PLC Earnings Presentation
Nov 18, 2014
Half Year 2014 Vectura Group PLC Earnings Release

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -23.20% -6.30%
Operating margin -36.60% -16.99%
EBITD margin - 11.78%
Return on average assets -3.00% -0.99%
Return on average equity -4.04% -1.27%
Employees 215 -
CDP Score - 52 D


One Prospect West
United Kingdom - Map
+44-1249-667700 (Phone)
+44-1249-667701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura�s products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company�s pharmaceutical business consists of the research, development and commercialization of pharmaceutical products. Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development. The Company�s products include NVA237, QVA149, VR315 EU & RoW, VR315 US, VR632 EU, VR632 US & RoW and VR315. Vectura has development collaborations and license agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). In March 2014, Vectura Group Plc acquired Activaero GmbH.

Officers and directors

Chris Paul Blackwell Ph.D. Chief Executive, Executive Director
Age: 52
Andrew J. Oakley Group Chief Financial Officer, Executive Director, Company Secretary
Age: 52
Trevor Michael Phillips Ph.D. Chief Operating Officer, President - US Operations, Director
Age: 53
Gerard Scheuch Chief Scientific Officer
Age: 58
Roger Heerman Chief Commercial Officer
Age: 41
Karl D. Keegan Ph.D. Chief Corporate Development Officer
Age: 48
Bruno F. J. Angelici Non-Executive Chairman of the Board
Age: 67
John Robert Brown Ph.D., CBE Senior Independent Non-Executive Director
Age: 59
Susan Elizabeth Foden Ph.D. Non-Executive Independent Director
Age: 61
Neil William Warner Non-Executive Independent Director
Age: 61